In 1998, Clay Siegall incorporated Seattle Genetics where he serves as the chairman of the board, president, and chief executive officer. Siegall’s work focuses on cancer therapies. Siegall formed the firm on the foundation of drug development practices, rigorous research, passion for helping others, and scientific innovation. Under his leadership, the firm has succeeded in developing antibody-drug conjugates. Seattle Genetics passed all the FDA requirements that resulted in the approval of ADCETRIS in 2011. Through a partnership with Takeda Pharmaceutical Company, the drug has been approved in over 65 countries. Additionally, Seattle Genetics is developing a variety of ADCs for treating cancer.
Seattle Genetics has entered into many strategic licenses for its technology of creating ADCs. Some of the companies that have benefited from the licenses include AbbVie, Pfizer, Genetech, and GlaxoSmithKline. These partnerships have generated over $350 million. Presently, over 20 companies are developing different drugs using Seattle Genetics’ technology. In addition, Clay Siegall has led the company’s capital raising campaigns. To date, he has secured $1.2 billion in financing, which includes the company’s initial public offering in 2001.
Before co-establishing Seattle Genetics, Siegall rendered his services at Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. He sits on the boards of Washington Roundtable, Ultragenyx, and Alder BioPharmaceuticals.
Speaking to ideamensch, Clay Siegall said that the idea of creating Seattle Genetics was inspired by his desire to help cancer patients. He set out to improve the tools available to oncologists after watching his father battle with cancer. At the time, he took note of the limited tools at the disposal of oncologists. Clay pointed out that his objective is to enhance the development of cancer therapies by undertaking comprehensive research.
About Clay Siegall
Clay Siegall is an accomplished scientist. He has made huge contributions to cancer research and treatment. Clay graduated with a B.S. in zoology from the University of Maryland. Siegall is also a graduate of the George Washington University where he earned his PhD in Genetics. Throughout his professional life, Siegall has received multiple awards, including the University of Maryland Alumnus of the Year Award for Natural Sciences, Math and Computer, and the Pacific Northwest Ernest & Young Entrepreneur of the Year Award.